Search
Trilostane
go.drugbank.com/drugs/DB01108ApprovedVet approvedWithdrawnIt was withdrawn from the United States market in April 1994.
AS-8112
go.drugbank.com/drugs/DB09207ExperimentalIt has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use. … AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.
Josamycin
go.drugbank.com/drugs/DB01321InvestigationalThe drug has antimicrobial activity against a wide spectrum of pathogens.
Tonapofylline
go.drugbank.com/drugs/DB12569InvestigationalTonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.
LI-301
go.drugbank.com/drugs/DB05509ExperimentalIt has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors.
Androstenedione
go.drugbank.com/drugs/DB01536IllicitInvestigationalDepending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol.
Teriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigationalTeriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Eu...
AT9283
go.drugbank.com/drugs/DB05169InvestigationalIt was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
Viral Macrophage-Inflammatory Protein
go.drugbank.com/drugs/DB15748ExperimentalViral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus...
Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigational[A229323] Trilaciclib was first described in the literature in 2016.[A229313] Trilaciclib was granted FDA approval on 12 February 2021.[L31823]